Mariana C. Castells, MD, PhD, Harvard Medical School, discusses mast cells. Dr Castells reviews the impact of mast cells on allergic reactions to food allergies and vaccines, and also discuss mast cell activation syndrome. Innovative treatments related to drug desensitization and allergy management are also discussed.
Avapritinib, branded as Ayvakit, became the first FDA-approved treatment for indolent systemic mastocytosis (ISM) in 2023, marking a major advancement for patients. ISM, driven by the KIT D816V…
In an expert roundtable discussion, Matthew P. Giannetti, MD, Harvard Medical School, Brigham and Women’s Hospital Mastocytosis Center, Boston, Massachusetts; Lauren M. Madigan, MD, University of Utah, University…
In an interview conducted at the 2024 American Society of Hematology Annual Meeting in San Diego, California, Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center,…
